Rusnáková Dominika Šmičková, Aziri Ramadan, Dubovan Peter, Jurík Miroslav, Mego Michal, Pinďák Daniel
Department of Surgical Oncology, Faculty of Medicine, Slovak Medical University and National Cancer Institute, 833 10 Bratislava, Slovak Republic.
Second Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, 833 10 Bratislava, Slovak Republic.
Oncol Lett. 2024 Oct 17;29(1):10. doi: 10.3892/ol.2024.14756. eCollection 2025 Jan.
Although advances in diagnostic techniques, new therapeutic strategies and personalization of breast cancer (BC) care have improved the survival for a number of patients, BC remains a major cause of morbidity and mortality for women. The study of circulating tumor cells (CTCs) has significant potential in translational oncology since these cells represent promising biomarkers throughout the entire course of BC in patients. CTCs also have notable prognostic value in early BC as well as metastatic BC. Based on current knowledge, it seems that the dynamics of CTCs that change during therapy reflect therapy response, and CTCs could serve as a tool for risk stratification and real-time monitoring of treatment in patients with BC. The question of how to use this information in everyday clinical practice and how this information can guide or change therapy to affect the clinical outcome of patients with BC remains unanswered. The present review aims to discuss current completed and ongoing trials that have been designed to demonstrate the clinical significance of CTCs, offer insights into treatment efficacy and assess CTC utility, facilitating their implementation in the routine management of patients with BC.
尽管诊断技术的进步、新的治疗策略以及乳腺癌（BC）护理的个性化改善了许多患者的生存率，但BC仍然是女性发病和死亡的主要原因。循环肿瘤细胞（CTC）的研究在转化肿瘤学中具有巨大潜力，因为这些细胞在BC患者的整个病程中都是很有前景的生物标志物。CTC在早期BC以及转移性BC中也具有显著的预后价值。基于目前的知识，似乎治疗期间变化的CTC动态反映了治疗反应，并且CTC可作为BC患者风险分层和治疗实时监测的工具。如何在日常临床实践中使用这些信息以及这些信息如何指导或改变治疗以影响BC患者的临床结局这一问题仍未得到解答。本综述旨在讨论目前已完成和正在进行的试验，这些试验旨在证明CTC的临床意义，深入了解治疗效果并评估CTC的效用，以促进其在BC患者常规管理中的应用。
